TXP Medical raises approximately 1.5 billion yen from ITOCHU and UTEC ~ Further acceleration of business through collaboration with the ITOCHU Group | TXP Medical Co. Ltd.

TXP Medical Co.Ltd. (headquarter; Chiyoda-ku, Tokyo, President; Tomohiro Sonoo, hereinafter "TXP Medical"), which provides the emergency medical data platform NEXT Stage ER, has issued new shares through a third-party allotment to ITOCHU Corporation (headquarter; Minato-ku Tokyo, President and COO; Keita Ishii, hereinafter "ITOCHU"), the University of Tokyo Edge Capital Partners Inc.(headquarter; Bunkyo-ku Tokyo, President; Tomotaka Gohji, hereinafter "UTEC"), an existing investor in TXP Medical, to raise approximately 1.5 billion yen in a Series B round of financing in April 2022. In conjunction with this fundraising, we opened a webpage (https://outlook.txpmedical.jp) on April 5, 2022, which explains our medium- to long-term business outlook and other information. In addition to explanations of our existing and new businesses, we will be holding a series of online events related to these businesses.

TXP Medical is a company that solves the medical information divide in the emergency medical field. TXP Medical provides hospitals with NEXT Stage ER, a product that digitizes the bucket relay of information (paper and telephone) between emergency medical services and hospitals, and easily converts unstructured data such as sentences in electronic medical records into structured data that can be easily used for medical research and other business purposes. This product will help hospitals to digitize emergency medical care and improve the quality of medical care based on data. This product enables the use of detailed medical data such as chief complaints, history, clinical diagnoses, and severity scores, which have been difficult to utilize because they are part of the text of medical records. This product targets large emergency center-class hospitals that receive a large number of emergency transports and play a key role in regional emergency medical care, with a market share of over 20% in the emergency center segment of university hospitals and over 500,000 cases of emergency patient information accumulated annually. In addition, NSER mobile, a mobile application equipped with an input-support AI function that realizes immediate information linkage between these hospitals and emergency medical services, is provided to local governments and through actual use in cities such as Kamakura and Toyota in Japan, NSER mobile has achieved appropriate emergency transport destination selection and reduced emergency transport time.We will continue to optimize acute care as a data platform across segments such as municipalities and hospitals.

While providing products to hospitals and local governments, TXP Medical will start clinical trial support services for pharmaceutical companies in 2021, utilizing the touch points with physicians created by these products and medical data obtained from these products. TXP Medical is strengthening its marketing activities as a service to shorten the clinical trial recruiting period for drugs for acute diseases, such as highly accurate site selection for clinical trials and real-time identification of patients for clinical trials.

The funds raised will be used to expand existing businesses to increase the speed of growth, as well as to launch several new businesses and strengthen the hiring of human resources to drive each of the related businesses in order to resolve the fragmentation of medical information in a wider range of areas, thereby further strengthening the promotion of each business. ITOCHU is also looking to collaborate with ITOCHU on the business side, and expects business synergies with many medical and healthcare-related companies, including ITOCHU Group's major CRO (contract research organization), A2 Healthcare, Inc.

【New Businesses】

Entry into the oncology field
By applying the medical record text structuring technology cultivated in the field of emergency medicine and the medical institution network, we will start offering NEXT Stage Oncology, a product for hospitals that converts medical record text and radiology/pathology reports into structured data in the field of oncology. The product aims to improve the quality of medical research and business efficiency through the development of structured data.
Strengthening Services for Pharmaceutical Companies
In addition to the aforementioned clinical trial support service, TXP Medical plans to launch an analysis service for medical data structured by our products and is preparing to acquire certification as an anonymized medical information provider under the Next Generation Medical Infrastructure Act and is aiming to implement anonymized processing of medical data from large-scale facilities, including national and public hospitals, and create business.
Overseas Expansion of Emergency Medical DX Products
We will deploy our main product, the NEXT Stage ER series, mainly in ASEAN countries. This is positioned as an initiative to export to the world high-level Japanese emergency medical services, which lead the world in terms of emergency transport operations, patient outcomes, and medical costs. The company is currently conducting a trial introduction of the system, mainly in large hospitals in Indonesia.

【New investor comments】

Tetsuya Asano, General Manager of Frontier Business Department, Information & Telecommunications Division, Information Technology & Finance Company, ITOCHU Corporation

TXP Medical's business policy of developing and providing solutions to solve real issues faced by doctors and healthcare professionals in the medical field is exactly the kind of "market-in" concept that we emphasize.

With this investment, we would like to contribute to the transformation of the medical and healthcare industries together with TXP Medical by accelerating collaboration with medical and healthcare-related companies in the ITOCHU Corporation and ITOCHU Group, and by promoting the efficiency of medical workplaces and the use of medical data.

【Comments from existing investors】

Hiroaki Kobayashi, Principal, The University of Tokyo Edge Capital Partners, Inc.

After the spectacular growth of the company since the Series A in July 2020, UTEC has made a solid additional investment in the Series B. It is wonderful that it has been able to achieve an overwhelming increase in name recognition, especially among emergency medical centers operated by university hospitals, and to rapidly expand NSER mobile, an emergency medical information system for emergency medical services, to municipalities around the country, backed by the advanced and unique nature of the product and high user satisfaction.